Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-06-22
1996-11-05
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514912, A61K 31445
Patent
active
055718230
ABSTRACT:
A method of controlling the abnormal postnatal growth of the eye of a maturing animal which comprises the ocular administration of therapeutically effective amounts of a dopamine antagonist.
REFERENCES:
patent: 4865599 (1989-09-01), Chiou
patent: 5055302 (1991-10-01), Laties et al.
patent: 5122522 (1992-06-01), Laties et al.
patent: 5284843 (1994-02-01), Stone et al.
patent: 5356892 (1994-10-01), Laties et al.
patent: 5360801 (1994-11-01), Laties et al.
patent: 5385939 (1995-01-01), Laties et al.
Mosinger et al. Gaba-like Immunoreactivity in the Vertebrate Retina: A Species Comparison Exp. Eye Res. 1986 42:631-644.
Fiszer DePlazas et al. Light and Dark Adaptation Infulences Gaba Receptor Sites in the Chick Retina Neurochemical Res. 1986 11:973-981.
Ikeda et al. Actions of baclofen and phaclofen upon ON- and Off- ganglion cells in the cat retina European J. Pharm. 1990 190:1.
Hoffmeister et al. Psychotropic Agents Part I Antipsychotics and Antidepressants, Zeelen F. Chemistry Structure and Activity Springer Verlag, New York 1980.
Stone et al. Muscarinic Antagonist Effects on Experimental Chick Myopia Exp. Eye Res. 1991 52:755-758.
Carter et al. Treating Blurred Vision Associated with Antipsychotic Medication Amer. Jour. Phychiatry 1977 134:941.
Meythaler et al. The Myopic and Miotic Effect of Pilocarpin and Glaucostat Albrecht v. Graefes Arch. Klin. Exp. Ophthal. 1971 181:234-245 published by .
Birdshall et al. Pirenzepine-a Ligant With Original Binding Properties to Muscarinic Receptors Scand. J. Gastro 1980 1-4.
Bedrossian R. The Effect of Atropine on Myopia Ophthalmology 1979 86:713-717.
Buckley et al. Antagonist Binding Properties of Five Cloned Muscarinic Receoptors Expressed in CHO K1 Cells Am Soc. Pharm. Exp. Ther. 35:469-476, 1980.
Curtain The Myopias-Basic Science and Chemical Management Harper & Row 1985 220-225.
Goss D. A. Attempts to Reduce the Rate of Increase of Myopia in Young People -A Critical Literature Review Am. Jour. Ophth. & Physc. Optics 1982 59:828-841.
Hagan et al. The Relative Potencies of Cholinominetics and Muscarinic Antagonists on the Rat Iris in Vivo: Efects of pH on Potency of Pirenzepine and Telenzepine NS Arch Pharmacology 1988 338:476-483.
Hammer et al. Selective Muscarinic Receptor Antagonists TIPS Jun. 1982.
Heathcote et al. Pirenzepine Selectively Inhibits Gastric Acid Secretion: a Comparative Pharmacological Study Between Pirenzepine and Seven Antiacetylcholine Drugs Scand. J. Gastro 1980 15-23.
Jaup et al. Comparison of the Action of Pirenzepine and L-Hyoscyamine on Gastric Acid Secretion and Other Muscarinic Effects Scand. J. Gastro 1980 89-94.
Jaup et al. Cerebrospinal Fluid Concentration of Pirenzepine After Therapeutic Dosage Scand. J. Gastro. 1980 35-37.
Lambrecht et al. o-Methoyoxy-sila-hexocyclium: a New Quaternary M.sub.1 -Selective Muscarinic Antagonist Euro. Journ. Pharm. 1988 151:155-156.
Meriney et al. Cholinergic Innervation of the Smooth Muscle Cells in the Ceroid Coat of the Chick Eye and its Developement j. Neuro. Sci. 1987 7:3827-3839.
Perr et al. Cyclic Nucleotides Regulate Collagen Production by Human Intestinal Smooth Muscle Cells Gastroenterology 1989 96:1521-1528.
Raviola et al. An Animal Model of Myopia N.E. Jour. Med. 1985 313:1162-1163.
Rubin et al. Myopia-A Treatable "Disease"?Survey of Ophthalmology 1976 21:65-69.
Scandinavian Journal of Gastroenterology Papers published ion 8 Jun. 1980 on Advances in Basic and Clinical Pharmacology of Pirenzepine, 1980.
Schudt C. The Affinity, Selectivity, and Biological Activity of Telenzepine Enantiomers Euro. Jour. Pharm. 1989 165:87-96.
Stone et al. Altered Retinal Amine Neurotransmitters in Form-Deprivation Myopia Soc. Neurosci. 1987 13:240.
Lin et al. Altered Dopamine Metabolism and Form-Derivation Myopia Invest. Ophth. Vis. Sci. 1988 29:33.
Taylor P. Pharmaceutical Basis of Therapeutics 1985 7th Ed. MacMillan Publ. Cholinergic Agonists Ch. 5, 100-108.
The Merck Index Eleventh Edition ed., Windholz 1989 80-780.
Francois et al. Ultrasonographic Study of the Effect of Different Miotics on the Eye Components Ophthalmologica, Basel 1977 175:328-338.
Iuvone et al., "Dopamine mediates the light-evoked suppression of serotonin N-acetyltransferase activity in retina, "Brain Res. 418:314-324, 1987.
The Merck Index, Tenth Edition, Martha Windholz, ed., 769:772, 1983.
Society of Neuroscience Meeting, Abstract, 71.14:240, Nov. 16-21, 1987.
Iuvone Paul M.
Laties Alan M.
Stone Richard A.
Emory University
Fay Zohreh
The Trustees of the University of Pennsylvania
LandOfFree
Pharmacological treatment of ocular development does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmacological treatment of ocular development, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmacological treatment of ocular development will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2015404